Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAR-UM-2: darovasertib + crizotinib versus investigator's choice as first-line treatment for HLA-A2-negative metastatic uveal melanoma
MOH_2023-11-27_013071Phase 3Not yet recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darovasertib and crizotinib in intraocular melanoma (3 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Progression-free survival and Overall survival. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
darovasertibcrizotinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on MOH_2023-11-27_013071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-27_013071.